patient registry News
-
Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry: for people affected by pelvic radiation during cancer treatment.
Pittsburgh, PA – (May 9, 2022) – Lipella Pharmaceuticals, Inc. is announcing the Radiation Cystitis Patient Registry, an on-line patient registry program for people who are affected by pelvic radiation exposure, including survivors of pelvic cancers, such as prostate, uterine, cervical and colon cancer. ...
-
Bladder Health Foundation Launches Patient Registry for Survivors of Pelvic Radiation Therapy
Pittsburgh, PA – (April 30, 2021) – The Bladder Health Foundation announces the rollout of the first on-line patient registry for pelvic radiation cancer survivors. The online registry is located at www.radiationcystitis.com The Bladder Health Foundation, with support from Lipella Pharmaceuticals Inc., is promoting the awareness of a serious bladder health condition, hemorrhagic ...
-
Healx pledges $25,000 to AKU Society patient registry campaign
Patient registries play a critical role in the development of treatments for rare diseases – 95% of which are still without an approved therapy today. Knowledge limitations around rare conditions are a huge barrier to treatment development and are compounded by the fact that rare disease patient populations are often small and geographically dispersed. Registries collect information ...
By Healx Ltd.
-
Graftys Announces Creation of an International Implant Registry to Follow up Graftys® HBS and Graftys® QuickSet
Aix-en-Provence, November 16th, 2015 – GRAFTYS SA, a company which develops and commercializes biomaterials used in orthopedic surgery, announces that it has recently established an ambitious Post Marketing Surveillance program, in the form of an internationally based registry of patients who have received implants of GRAFTYS® HBS and GRAFTYS® QuickSet. Both of these advanced ...
By Graftys
-
Inari Medical Announces Three New Data Sets to be Presented During Late-Breaking Clinical Trial Sessions at the 2022 TCT and VEINS Conferences
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced three new data sets will be presented during Late-Breaking Clinical Trial sessions at the 2022 TCT (Transcatheter Cardiovascular Therapeutics) and the 2022 VEINS (Venous Endovascular ...
-
Ivantis Announces 3 Year Results of Australian SPECTRUM Registry for Hydrus Microstent
Ivantis today announced long term results of the Australian cohort of the Global SPECTRUM registry. SPECTRUM is a post market patient registry for the Hydrus® Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with open-angle glaucoma in conjunction with cataract surgery or as a stand-alone procedure outside the United States. The SPECTRUM Registry was conceived in ...
-
Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACT
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive in-hospital and 30-day outcomes from the fully-enrolled 500-patient CLOUT registry. The company also reported positive results from a propensity-matched comparison of patients ...
-
Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (“PE”). The data was presented during a Late-Breaking Clinical Trial session at the 2022 ...
-
GT Medical Technologies Announces First Patient Treated in Registry Trial of GammaTile Therapy for Brain Tumors
GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced the first patient has been enrolled into its registry trial of GammaTile®, a FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for newly diagnosed malignant and recurrent brain tumors. The study will evaluate the safety and effectiveness of GammaTile Therapy in a ...
-
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the 2022 National Kidney Foundation Spring Clinical Meetings, taking place April 6-10, 2022 in Boston, Mass. ...
-
Evolution of ePROM: Advancements, Concerns, and the Way Forward
Patients’ directly reported outcomes in certain rare and chronic diseases are considered reliable for understanding the disease’s natural history, palliative treatments that focus primarily on symptom control, and quality of life. Electronic Patient-Reported Outcome Measures (ePROMs) are now allowing these patients to self-report health conditions and treatment effectiveness ...
-
xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting
Today, xCures announced that they will present two posters at the 27th Annual Meeting of the Society for Neuro-Oncology, from the 16th to the 20th of November 2022, in Tampa Bay, Florida. The Society for Neuro-Oncology is a multidisciplinary society of healthcare professionals dedicated to promoting advances in neuro-oncology through research and education. Their annual meeting features research ...
By xCures
-
Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstent
SPECTRUM, the world’s largest single-device registry in ophthalmology, has completed enrollment. The announcement was made today by Ivantis Inc., a company dedicated to developing new and innovative solutions for glaucoma. SPECTRUM is a patient registry for the Hydrus® Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with mild to moderate primary open-angle ...
-
Ivantis Recognized For Innovation, Excellence And Company Culture
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure in patients with open-angle glaucoma, is proud to be the recipient of multiple awards and recognition this year for its innovation and excellence in helping to change the standard of care for the world’s 80 million glaucoma patients, as well as its ...
-
Ivantis Announces Settlement of Glaukos Patent Litigation
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corporation to settle and dismiss all pending global litigation between them. Under the agreement’s terms, Ivantis has agreed to pay a total of ...
-
Longenesis announces Curator platform for privacy-preserving data use for COVID-19 research
Longenesis - a digital health startup aiming towards the acceleration of the biomedical research pipeline worldwide, announced a release of its product Curator. It is a platform where clinical institutions and patient organizations are connected in consortiums with potential collaboration partners and study sponsors to initiate further cooperation. The main difference between existing solutions - ...
By Longenesis
-
Recognizing 10 years of philanthropic support for prostate cancer research
Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation. Working with the Alberta Cancer Foundation and the University of Alberta, the Bird Dogs have enabled a new one-term, five-year chair position to further prostate cancer research — the Bird Dogs ...
-
Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent cataract surgery. Up to 80% ...
-
PreludeDx Presents DCIS Patient Data Comparing Clinicopathological Risk Factors to DCISionRT
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data comparing DCISionRT? and its integrated Residual Risk subtype (RRt) with traditional clinicopathology features at the 39th Annual Miami Breast Cancer Conference (MBCC), being held on March 3 – 6, 2022 at the Fontainebleau Miami ...
By PreludeDx
-
Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever release of five-year follow-up data from its HORIZON pivotal trial. This significant milestone represents the longest continuous follow-up of a MIGS device pivotal trial and comes on the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you